2021-03-10Impact Therapeutics Announced First-Patient-Dose of Wee1 Inhibitor IMP7068 in the U.S.
Impact Therapeutics announced today that the first patient was recently dosed in the first-in-human Phase 1 clinical study of Wee1 Inhibitor IMP7068 in the United States.
2021-02-09Impact Therapeutics Announced the IND Approval for its Wee1 Inhibitor IMP7068 from the NMPA
Impact Therapeutics announced today that the PRC National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) application of our Wee1 inhibitor IMP7068 to commence its clinical trial in China.
2020-12-01Impact Therapeutics Announces $50 Million Series C+ Financing
Impact therapeutics recently announced the completion of $50 million in Series C+ financing.
2020-11-17IMPACT announced PARP inhibitor Senaparib in combination with temozolomide IND clearance by US FDA
Impact Therapeutics recently announced that the U.S. FDA approved the Investigational New Drug (IND) application of PARP inhibitor senaparib (IMP4297) in combination with temozolomide (TMZ) for clinical study in U.S.
2020-11-13IMPACT announced Wee1 inhibitor IMP7068 IND clearance by US FDA
Impact Therapeutics recently announced that the U.S. FDA approved the Investigational New Drug (IND) application of Wee1 inhibitor IMP7068 for the first-in-human clinical study on October 29th, 2020.
2020-11-05Event Highlights: IMPACT 2020 R&D Day
On October 30th, IMPACT 2020 R&D Day was successfully held in Grand Hyatt Shanghai Hotel with a fascinating theme as "Hallmarks of Cancer and Synthetic Lethality".
2020-10-27Upcoming Event: IMPACT 2020 R&D Day
IMPACT 2020 R&D Day will be held on Oct 30, 2020 at Grand Hyatt Shanghai Hotel, China.
2020-08-20Impact Therapeutics and Junshi Biosciences Establish Joint Venture to Develop PARP Inhibitor Senapar
Impact Theraeutics, a privately held clinical-stage biopharmaceutical company devoted to the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality
2020-08-17Announcement: Dr. Alan D’Andrea Joined Scientific Advisory Board of Impact Therapeutics
Impact Therapeutics announced that Dr. Alan D'Andrea joined Scientific Advisory Board of the company.
2020-08-07Impact Announced Dosing of the First Patient in Senaparib and Temozolomide Combination Study
Impact Therapeutics announced that the first patient was dosed recently in the combination study of its PARP inhibitor senaparib (IMP4297) and temozolomide (TMZ). This study is a Phase I, open-label, multi-center, dose escalation and expansion study to ev